Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Stem Cells. Apr 26, 2014; 6(2): 69-81
Published online Apr 26, 2014. doi: 10.4252/wjsc.v6.i2.69
Published online Apr 26, 2014. doi: 10.4252/wjsc.v6.i2.69
Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions
Abraham S Kanate, Osborn Hematopoietic Malignancy and Transplantation program, Section of Hematology/Oncology, West Virginia University, Morgantown, WV 26506, United States
Marcelo C Pasquini, Parameswaran N Hari, Mehdi Hamadani, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, United States
Author contributions: All the authors contributed equally to this manuscript.
Correspondence to: Mehdi Hamadani, MD, Associate Professor of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, United States. mhamadani@mcw.edu
Telephone: +1-414-8050643 Fax: +1-414-8050643
Received: November 12, 2013
Revised: January 12, 2014
Accepted: March 13, 2014
Published online: April 26, 2014
Processing time: 167 Days and 8.5 Hours
Revised: January 12, 2014
Accepted: March 13, 2014
Published online: April 26, 2014
Processing time: 167 Days and 8.5 Hours
Core Tip
Core tip: Acute myeloid leukemia (AML) represents a heterogeneous group of high-grade myeloid neoplasms of the elderly with variable outcomes. We discuss the role of allo-hematopoietic cell transplantation (HCT) in AML patients stratified by cytogenetic- and molecular-risk in first complete remission, as well as allo-HCT as an option in relapsed/refractory AML.